CVS HEALTH Corp (CVS) Factsheet
Earnings-call transcript: none · IR deck: cataloged — watch a real agent read these end-to-end →
CVS HEALTH Corp (CVS) Stock Analysis
Analysis from 10-Q filed 2026-11-04. Data as of Q3 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 9.8%. FCF margin 3.7%. D/E 0.8x. Source: 10-Q filed 2026-11-04.
| Metric | Value | Context |
|---|---|---|
| ROIC | 9.8% | Near cost of capital |
| FCF Margin | 3.7% | Cash flow pressure |
| Debt/Equity | 0.8x | Moderate leverage |
ROIC 9.8% — Top 50% of sector peers. FCF margin 3.7% — Top 50%.
Explore CVS HEALTH Corp: Earnings History | Overview
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for CVS: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_section, get_metric_history, compare_companies, screen_filing_signals.
Profitability: CVS HEALTH Corp earns 9.8% ROIC, Top 50% in Consumer Discretionary
ROIC TTM 9.8%, sector median 6.8%, Top 50%. DuPont: NOPAT margin 3.3% × asset turnover 1.7x. Gross margin 44.2%. Operating margin 3.6%. Source: 10-Q filed 2026-11-04.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 9.8% | Adequate | Above sector median of 6.8% |
| Return on Equity (ROE) | 14.3% | Adequate | Moderate equity returns |
| Gross Margin | 44.2% | Good | Strong pricing power |
| Operating Margin | 3.6% | Warning | Moderate operational efficiency |
Cash Flow: CVS HEALTH Corp generates $15.6B FCF at 3.7% margin, positive NaN/8 quarters
FCF TTM $15.6B. FCF margin 3.7%, Top 50%. OCF/Net income 1.7x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2026-11-04.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 3.7% | Warning | Thin cash margins |
| Free Cash Flow (TTM) | $15.6B | Good | Positive cash generation |
| OCF/Net Income | 1.7x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: CVS HEALTH Corp at 0.8x leverage, 4.9x interest coverage
Debt/Equity 0.8x. Total debt $60.7B, cash & investments $14.9B. Interest coverage 4.9x. Source: 10-Q filed 2026-11-04.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.8x | Adequate | Moderate leverage |
| Net Cash Position | $-45.8B | Warning | Net debt position |
| Interest Coverage | 4.9x | Adequate | Monitor debt obligations |
Valuation: CVS HEALTH Corp trades at 10.4x earnings
P/E 10.4x. EV/Sales 0.4x. FCF yield 13.5%. Dividend yield 3.0%. Source: 10-Q filed 2026-11-04.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| P/E Ratio | 10.4x | Adequate | Reasonable valuation |
| EV/Sales | 0.4x | Excellent | Attractive revenue multiple |
| FCF Yield | 13.5% | Excellent | Attractive cash return |
| Dividend Yield | 3.0% | Adequate | Growth focus over income |
Capital Allocation: CVS HEALTH Corp returns 3.0% shareholder yield
Total shareholder yield 3.0% (div 3.0%). Share count +0.8% YoY. Capital returned $3.4B TTM. Source: 10-Q filed 2026-11-04.
| Metric | CVS | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.0% | Adequate | Dividend + buyback yield combined |
| Share Count Change (YoY) | 0.8% | Adequate | Net dilution from issuance/SBC |
| Total Capital Returned (TTM) | $3.4B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 9.8% | Top 50% | 1.4x above |
| Free Cash Flow Margin | 3.7% | Top 50% | 1.1x above |
| Gross Margin | 44.2% | Top 50% | 1.2x above |
| Operating Margin | 3.6% | Bottom 50% | 0.8x below |
| Return on Equity (ROE) | 14.3% | Top 50% | 1.3x above |
| P/E Ratio | 10.4x | N/A | - |
Financial Scorecard
| Metric | CVS | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 9.8% | Adequate | Top 50% of sector (median: 6.8%) |
| Free Cash Flow Margin | 3.7% | Warning | Top 50% of sector (median: 3.2%) |
| Gross Margin | 44.2% | Good | Top 50% of sector (median: 38.1%) |
| Debt to Equity Ratio | 75.4% | Adequate | Elevated but manageable |
| P/E Ratio (Price-to-Earnings) | 10.4x | Adequate | Attractively valued |
| Free Cash Flow Yield | 13.5% | Excellent | High cash return |
Frequently Asked Questions
Q: What is CVS HEALTH Corp's Return on Invested Capital (ROIC)?
CVS HEALTH Corp (CVS) has a trailing twelve-month Return on Invested Capital (ROIC) of 9.8%. The 8-quarter median ROIC is 7.0% with a improving trend. Sector median 6.8%. Source: 10-Q filed 2026-11-04.
Q: What is CVS HEALTH Corp's Free Cash Flow Margin?
CVS HEALTH Corp (CVS) has a free cash flow margin of 3.7%, generating $15.6 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2026-11-04.
Q: What is CVS HEALTH Corp's P/E ratio and how does it compare to peers?
CVS HEALTH Corp (CVS) trades at a P/E ratio of 10.4x, which is above the sector median of N/A. EV/Sales 0.4x. FCF yield 13.5%. Source: 10-Q filed 2026-11-04.
Q: Does CVS HEALTH Corp pay a dividend?
CVS HEALTH Corp (CVS) currently pays a dividend yield of 3.0%. Total shareholder yield (dividend + buybacks) 3.0%. Source: 10-Q filed 2026-11-04.
Q: How much debt does CVS HEALTH Corp have?
CVS HEALTH Corp (CVS) has a debt-to-equity ratio of 0.8x with total debt of $60.7 billion. Interest coverage 4.9x. Net debt $45.8 billion. Source: 10-Q filed 2026-11-04.
Q: What is CVS HEALTH Corp's revenue and earnings growth?
CVS HEALTH Corp (CVS) grew revenue by 6.7% year-over-year. EPS +2217.6% YoY. Source: 10-Q filed 2026-11-04.
Q: How does CVS HEALTH Corp compare to competitors in Consumer Discretionary?
Compared to other companies in Consumer Discretionary, CVS HEALTH Corp (CVS) shows: ROIC 9.8%, sector median 6.8% (Top 50%). FCF margin 3.7%, sector median 3.2% (Top 50%). Gross margin 44.2%, 6.1pp above sector median. These rankings are based on MetricDuck's analysis of all Consumer Discretionary companies with available SEC filings.
Q: What warning signs should I watch for with CVS HEALTH Corp?
Quantitative warning flags for CVS HEALTH Corp (CVS): 1) FCF margin 3.7% (below 5%). Source: 10-Q filed 2026-11-04.
Data Source: Data sourced from 10-Q filed 2026-11-04. TTM metrics as of Q3 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms